antiPD1 Archives

Targeting LINC01711 in FAP+ cancer-associated fibroblasts overcomes lactate-mediated immunosuppression and

Dr AF Saeed Dr AF Saeed 25th August 2025

Targeting LINC01711 in FAP+ cancer-associated fibroblasts overcomes lactate-mediated immunosuppression and enhances anti-PD-1 efficacy in lung adenocarcinoma Summary Targeting LINC01711 in cancer-associated fibroblasts (CAFs) expressing fibroblast activation protein (FAP) shows promise in overcoming immunosuppression in lung Read More

Education, Research & Positions

Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy – New

Dr AF Saeed Dr AF Saeed 20th August 2025

Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy Summary Cancer-induced nerve damage can foster resistance to anti-PD-1 immunotherapy. Specifically, nerves damaged by the tumor release neuropeptides that suppress immune cell activity, particularly T cell function. Read More

Education, Research & Positions

Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG

Dr AF Saeed Dr AF Saeed 14th August 2025

Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial Summary The SWOG S1512 phase 2 trial investigated pembrolizumab (anti-PD-1 therapy) in patients with unresectable desmoplastic melanoma (DM), a rare and aggressive subtype. The study Read More

Education, Research & Positions

Profiling with senescence-associated secretory phenotype score identifies GDC-0879 as a

Dr AF Saeed Dr AF Saeed 8th August 2025

Profiling with senescence-associated secretory phenotype score identifies GDC-0879 as a small molecule sensitizing glioblastoma to anti-PD1 Summary Glioblastoma (GBM) is a deadly brain cancer with limited treatment options, and immunotherapy’s effectiveness is often hindered. Read More

Education, Research & Positions

Bifidobacterium boosts anti-PD-1 effectiveness through JAK pathway in hepatocellular carcinoma

Dr AF Saeed Dr AF Saeed 23rd July 2025

Bifidobacterium boosts anti-PD-1 effectiveness through JAK pathway in hepatocellular carcinoma Summary A study reveals that Bifidobacterium species enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma (HCC). The mechanism involves Bifidobacterium modulating the gut microbiome, Read More

Education, Research & Positions

Impaired autophagy by cepharanthine induces immunogenic cell death and enhances

Dr AF Saeed Dr AF Saeed 4th July 2025

Impaired autophagy by cepharanthine induces immunogenic cell death and enhances anti-PD-1 response in MSS-type colorectal cancer Summary Cepharanthine, a drug known to impair autophagy, shows promise in enhancing anti-PD-1 immunotherapy for MSS-type colorectal cancer (CRC), Read More

Education, Research & Positions

Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and

Dr AF Saeed Dr AF Saeed 3rd July 2025

Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies Summary Tumour-resident memory T cells (Trm) are critical for effective cancer immunotherapy, but their heterogeneity and specific roles remain unclear. Research reveals Read More

Education, Research & Positions

Resistance to anti-PD-1 therapy is driven by CD30+ regulatory T

Dr AF Saeed Dr AF Saeed 29th June 2025

Resistance to anti-PD-1 therapy is driven by CD30+ regulatory T cell activity Summary Resistance to anti-PD-1 immunotherapy, a common cancer treatment, is often linked to the suppressive activity of CD30-expressing regulatory T cells (Tregs). Read More